AU2003304237A1 - Gel-stabilized nanoparticulate active agent compositions - Google Patents

Gel-stabilized nanoparticulate active agent compositions

Info

Publication number
AU2003304237A1
AU2003304237A1 AU2003304237A AU2003304237A AU2003304237A1 AU 2003304237 A1 AU2003304237 A1 AU 2003304237A1 AU 2003304237 A AU2003304237 A AU 2003304237A AU 2003304237 A AU2003304237 A AU 2003304237A AU 2003304237 A1 AU2003304237 A1 AU 2003304237A1
Authority
AU
Australia
Prior art keywords
active agent
solid
nanoparticulate active
gel
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003304237A
Other languages
English (en)
Other versions
AU2003304237A8 (en
Inventor
David A. Czekai
Simon L. Mcgurk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of AU2003304237A1 publication Critical patent/AU2003304237A1/en
Publication of AU2003304237A8 publication Critical patent/AU2003304237A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
AU2003304237A 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions Abandoned AU2003304237A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40958702P 2002-09-11 2002-09-11
US60/409,587 2002-09-11
PCT/US2003/028380 WO2005000265A2 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions

Publications (2)

Publication Number Publication Date
AU2003304237A1 true AU2003304237A1 (en) 2005-01-13
AU2003304237A8 AU2003304237A8 (en) 2005-01-13

Family

ID=33551184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003304237A Abandoned AU2003304237A1 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions

Country Status (13)

Country Link
US (1) US7713551B2 (enExample)
EP (1) EP1553927B9 (enExample)
JP (1) JP4878839B2 (enExample)
AT (1) ATE487470T1 (enExample)
AU (1) AU2003304237A1 (enExample)
CA (1) CA2498207C (enExample)
CY (1) CY1110949T1 (enExample)
DE (1) DE60334924D1 (enExample)
DK (1) DK1553927T3 (enExample)
ES (1) ES2355723T3 (enExample)
PT (1) PT1553927E (enExample)
SI (1) SI1553927T1 (enExample)
WO (1) WO2005000265A2 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
DE60332212D1 (de) * 2002-02-04 2010-06-02 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
AU2003301654A1 (en) * 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
US7955288B2 (en) * 2002-12-11 2011-06-07 Ferrosan Medical Devices A/S Gelatine-based materials as swabs
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP2007519450A (ja) * 2004-01-30 2007-07-19 フェロサン アー／エス 止血用のスプレーおよび組成物
EP1742612A2 (en) * 2004-05-06 2007-01-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US8021684B2 (en) * 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
DE102004041340A1 (de) * 2004-08-20 2006-02-23 Deutsche Gelatine-Fabriken Stoess Ag Nanopartikel und Verfahren zu deren Herstellung
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
DE602006012671D1 (de) * 2005-06-03 2010-04-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat-formulierungen
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EP1901728A2 (en) * 2005-06-03 2008-03-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1931340A2 (en) * 2005-06-15 2008-06-18 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US9119899B2 (en) * 2006-01-18 2015-09-01 Cormatrix Cardiovascular, Inc. Method and system for treatment of cardiovascular disorders
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
PL2135603T3 (pl) * 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
EP1962795A1 (en) * 2005-12-07 2008-09-03 PharmaKodex Ltd Topical compositions for paediatric use
UA96936C2 (uk) 2005-12-29 2011-12-26 Лексикон Фармасьютикалз, Инк. Поліциклічні похідні амінокислот і їх застосування
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
ES2448472T3 (es) * 2006-05-26 2014-03-14 José Antonio Cruz Serrano Gel de proteína y procedimiento para su elaboración
MX2008015275A (es) * 2006-05-30 2009-02-06 Elan Pharma Int Ltd Formulaciones de posaconazol en nanoparticulas.
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
JP2009541359A (ja) * 2006-06-23 2009-11-26 エラン・ファルマ・インターナショナル・リミテッド ナノ粒子状ナプロキセンおよび制御放出ヒドロコドンを含む組成物
US20080213374A1 (en) * 2006-07-10 2008-09-04 Elan Pharma International Limited Nanoparticulate sorafenib formulations
KR100809903B1 (ko) 2006-09-05 2008-03-06 주식회사유한양행 안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물
EP2089005B1 (en) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008115820A1 (en) * 2007-03-16 2008-09-25 Elan Corporation Plc Combination of a narcotic and a non-narcotic analgesic
KR100761041B1 (ko) 2007-03-22 2007-10-04 현대약품 주식회사 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물
KR100761040B1 (ko) 2007-03-22 2007-10-04 현대약품 주식회사 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물
US8119600B2 (en) * 2007-04-10 2012-02-21 Stefano Ferrari Compositions containing lysozyme and C-1/C-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PT103765A (pt) * 2007-06-20 2008-12-22 Inst Superior Tecnico Síntese e aplicação de uma família de novos materiais resultantes do cruzamento entre gelatina e sais orgânicos
WO2009073205A1 (en) * 2007-12-07 2009-06-11 Biocure, Inc. Bone substitute
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US8389012B2 (en) * 2008-03-07 2013-03-05 The Corporation Of Mercer University Gellan-gum nanoparticles and methods of making and using the same
KR20110007095A (ko) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
WO2010146407A1 (en) * 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
CN102711749A (zh) 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
US20130137635A1 (en) 2010-02-10 2013-05-30 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
GB201006218D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
CA2811202A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off-flavor masking agent
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
PL2672983T3 (pl) * 2011-02-11 2017-10-31 Edge Therapeutics Inc Kompozycje i sposoby polepszania rokowania u człowieka z krwotokiem podpajęczynówkowym
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
CN103635178A (zh) * 2011-04-11 2014-03-12 阿扬达集团 口服药物分散组合物
EP2540287A1 (en) 2011-07-01 2013-01-02 FutureChemistry Continuous flow production of gelatin nanoparticles
WO2013035423A1 (ja) * 2011-09-09 2013-03-14 東洋カプセル株式会社 カンデサルタンシレキセチル含有医薬組成物
WO2013131520A2 (en) 2012-03-06 2013-09-12 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
KR20160081646A (ko) * 2014-12-31 2016-07-08 건일제약 주식회사 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
CN105981748B (zh) * 2015-05-07 2018-12-04 博约生物科技(苏州)有限公司 一种提取天然抑菌剂有效成分的方法
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019072877A1 (en) 2017-10-10 2019-04-18 Capsugel Belgium Nv GETTING MULTIPARTICULAR COMPOSITIONS
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
EP4072559A4 (en) 2019-12-06 2023-06-21 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4122453A1 (en) * 2021-07-22 2023-01-25 Universität Heidelberg Thermoreversible gelatin matrix for stability enhancement and ready-to-use liquid application of nanoparticles and colloidal drugs
MX2024010565A (es) 2022-03-02 2024-09-06 Horizon Therapeutics Ireland Dac Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2.
CN117186267B (zh) * 2022-05-31 2025-01-28 杭州协合医疗用品有限公司 一种羟丁基甲壳素、羟丁基甲壳素水凝胶及制备方法
WO2025216570A1 (ko) * 2024-04-10 2025-10-16 주식회사 인벤테라 림프관으로 배출 가능하고 면역원성이 감소된 다당류 가교 콜로이드 입자 기반 기능성 약물

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003999A (en) * 1972-10-25 1977-01-18 A. H. Robins Company, Incorporated Aspirin-tea coprecipitates for treating inflammation
US4486412A (en) 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
US4882157A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for anti-cholesterolemics
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4837255A (en) * 1987-03-10 1989-06-06 Ciba-Geigy Corporation Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
ATE137962T1 (de) * 1991-12-05 1996-06-15 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DE4140179C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
CA2213638C (en) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
EP0833621B1 (en) 1995-06-09 2002-01-30 R.P. Scherer Technologies, Inc. Soft gelatin capsules containing particulate material
DE69620771T3 (de) * 1995-09-19 2006-04-27 Alcan International Ltd., Montreal Verwendung von gewalzten Aluminiumlegierungen für Konstruktionsteile von Fahrzeugen
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
NL1009107C2 (nl) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel.
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6258380B1 (en) 1999-03-05 2001-07-10 Banner Pharmacaps, Inc. Chewable soft capsule
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ATE271922T1 (de) 1999-06-01 2004-08-15 Elan Pharma Int Ltd Kleinmühle und verfahren dafür
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
AU2001257315A1 (en) 2000-04-26 2001-11-20 Elan Pharma International, Ltd. Apparatus for sanitary wet milling
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6685961B1 (en) 2000-10-24 2004-02-03 Banner Pharmacaps, Inc. Colored gelatin-based formulations and method
JP4223390B2 (ja) 2001-06-05 2009-02-12 エラン・ファルマ・インターナショナル・リミテッド 材料をフライス削りするシステムおよび方法
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
US20060088590A1 (en) 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
WO2007050975A2 (en) 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms

Also Published As

Publication number Publication date
US7713551B2 (en) 2010-05-11
CA2498207A1 (en) 2005-01-06
JP2006514688A (ja) 2006-05-11
US20050031691A1 (en) 2005-02-10
DK1553927T3 (da) 2011-01-31
EP1553927B1 (en) 2010-11-10
ATE487470T1 (de) 2010-11-15
SI1553927T1 (sl) 2010-12-31
AU2003304237A8 (en) 2005-01-13
PT1553927E (pt) 2010-11-22
JP4878839B2 (ja) 2012-02-15
CA2498207C (en) 2012-03-13
DE60334924D1 (de) 2010-12-23
CY1110949T1 (el) 2015-06-10
EP1553927B9 (en) 2011-09-21
WO2005000265A2 (en) 2005-01-06
EP1553927A2 (en) 2005-07-20
WO2005000265A3 (en) 2005-05-12
ES2355723T3 (es) 2011-03-30

Similar Documents

Publication Publication Date Title
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
DE60202794D1 (de) Orodispersible tablette mit hoher homogenität und herstellungsverfahren dafür
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
ES2125099T3 (es) Composiciones que comprenden nanoparticulas de un antiinflamatorio no estereoideo.
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
MXPA05012753A (es) Composiciones cosmeticas estables que comprenden un agente autobronceador.
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
DE50007327D1 (de) Antitranspirant-zusammensetzung enthaltend einen wasserlöslichen antitranspirant-wirkstoff
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
ME00568A (en) Ciclesonide-containing aqueous pharmaceutical composition
WO2004032843A3 (en) Mucoadhesive tetracycline formulations
WO2004000223A3 (en) Rapidly disintegrating formulations for treating or preventing mucositis
DE60212088D1 (de) Wasserfreie schweisshemende oder desodorierende zusammensetzungen enthaltend einen festen, wasserlöslichen hautpflegenden wirkstoff und glycerin
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
US20040023937A1 (en) Anti-cancer formulation
UA96257C2 (uk) Стабілізована фармацевтична композиція лейкотриєн-b4 (ltb4) агента
AR039314A1 (es) Formulaciones farmaceuticas de liberacion retrasada
MX9604984A (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase